PPAR Agonists for the Prevention and Treatment of Lung Cancer
Lung cancer is the most common and most fatal of all malignancies worldwide. Furthermore, with more than half of all lung cancer patients presenting with distant metastases at the time of initial diagnosis, the overall prognosis for the disease is poor. There is thus a desperate need for new prevent...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2017/8252796 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564054562963456 |
|---|---|
| author | Sowmya P. Lakshmi Aravind T. Reddy Asoka Banno Raju C. Reddy |
| author_facet | Sowmya P. Lakshmi Aravind T. Reddy Asoka Banno Raju C. Reddy |
| author_sort | Sowmya P. Lakshmi |
| collection | DOAJ |
| description | Lung cancer is the most common and most fatal of all malignancies worldwide. Furthermore, with more than half of all lung cancer patients presenting with distant metastases at the time of initial diagnosis, the overall prognosis for the disease is poor. There is thus a desperate need for new prevention and treatment strategies. Recently, a family of nuclear hormone receptors, the peroxisome proliferator-activated receptors (PPARs), has attracted significant attention for its role in various malignancies including lung cancer. Three PPARs, PPARα, PPARβ/δ, and PPARγ, display distinct biological activities and varied influences on lung cancer biology. PPARα activation generally inhibits tumorigenesis through its antiangiogenic and anti-inflammatory effects. Activated PPARγ is also antitumorigenic and antimetastatic, regulating several functions of cancer cells and controlling the tumor microenvironment. Unlike PPARα and PPARγ, whether PPARβ/δ activation is anti- or protumorigenic or even inconsequential currently remains an open question that requires additional investigation. This review of current literature emphasizes the multifaceted effects of PPAR agonists in lung cancer and discusses how they may be applied as novel therapeutic strategies for the disease. |
| format | Article |
| id | doaj-art-56bbb084cd314d1f803bed0b8cf46a1a |
| institution | Kabale University |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-56bbb084cd314d1f803bed0b8cf46a1a2025-02-03T01:11:58ZengWileyPPAR Research1687-47571687-47652017-01-01201710.1155/2017/82527968252796PPAR Agonists for the Prevention and Treatment of Lung CancerSowmya P. Lakshmi0Aravind T. Reddy1Asoka Banno2Raju C. Reddy3Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USADepartment of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USADepartment of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USADepartment of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USALung cancer is the most common and most fatal of all malignancies worldwide. Furthermore, with more than half of all lung cancer patients presenting with distant metastases at the time of initial diagnosis, the overall prognosis for the disease is poor. There is thus a desperate need for new prevention and treatment strategies. Recently, a family of nuclear hormone receptors, the peroxisome proliferator-activated receptors (PPARs), has attracted significant attention for its role in various malignancies including lung cancer. Three PPARs, PPARα, PPARβ/δ, and PPARγ, display distinct biological activities and varied influences on lung cancer biology. PPARα activation generally inhibits tumorigenesis through its antiangiogenic and anti-inflammatory effects. Activated PPARγ is also antitumorigenic and antimetastatic, regulating several functions of cancer cells and controlling the tumor microenvironment. Unlike PPARα and PPARγ, whether PPARβ/δ activation is anti- or protumorigenic or even inconsequential currently remains an open question that requires additional investigation. This review of current literature emphasizes the multifaceted effects of PPAR agonists in lung cancer and discusses how they may be applied as novel therapeutic strategies for the disease.http://dx.doi.org/10.1155/2017/8252796 |
| spellingShingle | Sowmya P. Lakshmi Aravind T. Reddy Asoka Banno Raju C. Reddy PPAR Agonists for the Prevention and Treatment of Lung Cancer PPAR Research |
| title | PPAR Agonists for the Prevention and Treatment of Lung Cancer |
| title_full | PPAR Agonists for the Prevention and Treatment of Lung Cancer |
| title_fullStr | PPAR Agonists for the Prevention and Treatment of Lung Cancer |
| title_full_unstemmed | PPAR Agonists for the Prevention and Treatment of Lung Cancer |
| title_short | PPAR Agonists for the Prevention and Treatment of Lung Cancer |
| title_sort | ppar agonists for the prevention and treatment of lung cancer |
| url | http://dx.doi.org/10.1155/2017/8252796 |
| work_keys_str_mv | AT sowmyaplakshmi pparagonistsforthepreventionandtreatmentoflungcancer AT aravindtreddy pparagonistsforthepreventionandtreatmentoflungcancer AT asokabanno pparagonistsforthepreventionandtreatmentoflungcancer AT rajucreddy pparagonistsforthepreventionandtreatmentoflungcancer |